Biocryst Pharmaceuticals reported $24.02M in Interest Expense on Debt for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Interest Expense On Debt Change
Alnylam Pharmaceuticals ALNY:US $ 42.61M 247K
Biocryst Pharmaceuticals BCRX:US $ 24.02M 0.18M
Chemocentryx CCXI:US $ 0.59M 0.01M
Gilead Sciences GILD:US $ 242M 4M
IONIS PHARMACEUT IONS:US $ 2.13M 0.01M
Karyopharm Therapeutics KPTI:US $ 6.31M 371K
Neurocrine Biosciences NBIX:US $ 2.2M 0.4M
Ptc Therapeutics PTCT:US $ 22.28M 1.34M
Regeneron Pharmaceuticals REGN:US $ 13.1M 0.5M
Sarepta Therapeutics SRPT:US $ 16.03M 0.23M
Vertex Pharmaceuticals VRTX:US $ 14.6M 0.3M
YTE INCY:US $ 0.68M 0M